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An increase in calorie consumption is associated with the recent rise in obesity prevalence.
However, our current understanding of the effects of nutrient excess on major metabolic
pathways appears insufficient to develop safe and effective metabolic interventions to
prevent obesity. Hence, we sought to identify systemic metabolic changes caused by
nutrient excess and to determine how endothelial nitric oxide synthase (eNOS)—which
has anti-obesogenic properties—affects systemic metabolism by measuring plasma
metabolites. Wild-type (WT) and eNOS transgenic (eNOS-TG) mice were placed on
low fat or high fat diets for 6 weeks, and plasma metabolites were measured using
an unbiased metabolomic approach. High fat feeding in WT mice led to significant
increases in fat mass, which was associated with significantly lower plasma levels
of 1,5-anhydroglucitol, lysophospholipids, 3-dehydrocarnitine, and bile acids, as well as
branched chain amino acids (BCAAs) and their metabolites. Plasma levels of several lipids
including sphingomyelins, stearoylcarnitine, dihomo-linoleate and metabolites associated
with oxidative stress were increased by high fat diet. In comparison with low fat-fed WT
mice, eNOS-TG mice showed lower levels of several free fatty acids, but in contrast, the
levels of bile acids, amino acids, and BCAA catabolites were increased. When placed on
a high fat diet, eNOS overexpressing mice showed remarkably higher levels of plasma
bile acids and elevated levels of plasma BCAAs and their catabolites compared with WT
mice. Treatment with GW4064, an inhibitor of bile acid synthesis, decreased plasma
bile acid levels but was not sufficient to reverse the anti-obesogenic effects of eNOS
overexpression. These findings reveal unique metabolic changes in response to high fat
diet and eNOS overexpression and suggest that the anti-obesity effects of eNOS are likely
independent of changes in the bile acid pool.
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INTRODUCTION
The relatively recent increase in obesity prevalence is associated
with a heightened risk for developing type 2 diabetes (Ervin, 2009;
Roger et al., 2012) as well as a risk of developing chronic dis-
eases such as cardiovascular disease and cancer (Calle et al., 1999).
In principle, obesity is related to a state of energy imbalance,
which is impacted by both nutrient overconsumption or insuf-
ficient energy expenditure (Tseng et al., 2010). Excessive caloric
intake may be responsible, at least partially, for the high preva-
lence of obesity in industrialized societies. In the US, the average
consumption of calories, derived mostly from high fat-containing
foods, has increased by >200 kcal/d per person over the past few
decades (Hill and Peters, 1998; Nielsen and Popkin, 2003; Briefel
and Johnson, 2004; Kant and Graubard, 2004). The metabolic
changes occurring under these conditions are responsible for or
permissive in the development of pre-diabetic and diabetic states.
Hence, an understanding of how nutrient excess affects systemic
and organ-specific metabolism could lead to the identification of
new therapeutic targets to prevent obesity and mitigate risk of
developing a range of chronic diseases.
Systemic and organ-specific metabolism are regulated by
a host of autocrine and paracrine factors such as insulin,
adipokines, and nitric oxide (NO). While peptide hormones have
been extensively studied, the role of NO in regulating metabolism
is less well known. Nevertheless, several studies show that NO
bioavailability is decreased in animal models of diabetes and
obesity (Bender et al., 2007; Kim et al., 2008) as well as in
humans with metabolic disease (Higashi et al., 2001; Gruber
et al., 2008). Mice lacking endothelial NO synthase (eNOS), a
key source of NO in vivo, are insulin resistant, have impaired
fatty acid oxidation and display exaggerated high fat diet (HFD)-
induced weight gain (Shankar et al., 2000; Duplain et al., 2001;
Cook et al., 2003), and, the abundance of eNOS is remark-
ably diminished in obesity and diabetes (Valerio et al., 2006;
Perez-Matute et al., 2009; Georgescu et al., 2011; Kraus et al.,
2012; Sansbury et al., 2012). In addition, conditions of nutrient
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excess lead to uncoupling of eNOS (Cai et al., 2005; Yamamoto
et al., 2010; Forstermann and Li, 2011; Kietadisorn et al., 2012;
Abudukadier et al., 2013) which increases the production of
superoxide and decreases NO bioavailability. These observations
suggest that conditions of obesity and diabetes significantly affect
NO production and bioavailability, which in turn could atten-
uate the regulation of metabolism by NO. In support of this
view, we have recently reported that genetic overexpression of
eNOS (to enhance NO production) inmice prevents diet-induced
obesity, increases metabolic activity, and promotes a brown-like
adipocyte phenotype in white adipose tissue (Sansbury et al.,
2012). Similarly, constitutive activation of eNOS, by knocking in
a phosphomimetic point mutation at S1176 of the enzyme, pro-
motes resistance to diet-induced weight gain (Kashiwagi et al.,
2013). Hence, both gain- and loss-of-function studies suggest
eNOS-derived NO plays a critical role in regulating systemic
metabolism.
Although it is evident that NO can markedly affect systemic
metabolism, the specific metabolic pathways regulated by NO
remain unclear. In cell culture systems, NO has been shown to
regulate metabolic pathways such as the hexose monophosphate
shunt (Clancy et al., 1997) and glycolysis (Almeida et al., 2004).
Nevertheless, whether NO can exert similar metabolic control
in vivo has not been investigated and specific metabolites affected
by NO have not been identified. Moreover, even though NO
can promote mitochondrial biogenesis (Nisoli et al., 2003, 2004;
Kelly and Scarpulla, 2004), it can paradoxically inhibit mito-
chondrial respiration acutely by binding to cytochrome oxidase
(Shiva et al., 2005; Cooper and Giulivi, 2007). How such diverse
actions of NO integrate to regulate systemic metabolism remain
to be elucidated. In this study, we used an unbiased metabolomic
approach to examine changes in plasma metabolite profiles of
wild type (WT) and eNOS transgenic (eNOS-TG) mice fed low
fat or high fat diets and determined whether changes in spe-
cific metabolic pathways contribute to the lean phenotype of
eNOS-TG mice.
METHODS
ANIMAL STUDIES
All procedures were approved by the University of Louisville
Institutional Animal Care and Use Committee. C57BL/6J (WT)
and eNOS transgenic (eNOS-TG) mice on the same genetic back-
ground were used for all experiments. The eNOS-TGmice express
bovine eNOS under the control of the preproendothelin-1 pro-
moter (Ohashi et al., 1998; Sansbury et al., 2012). At 8 weeks
of age, male mice were placed on a low (10%) fat diet (LFD;
Research Diets, Inc., #D12450B), a high (60%) fat diet (HFD;
Research Diets Inc., #D12492) or a custom-formulated HFD con-
taining GW4064, for 6 weeks. The custom GW4064 diet was
produced by Research Diets Inc. and was formulated by adding
GW4064 (Sigma, #G5172) to the HFD (#D12492) at a concentra-
tion of 180mg of compound/kg of diet, as described previously
(Watanabe et al., 2011). Water and food were provided ad libi-
tum. Body weights were recorded weekly. At the end of the feeding
protocol, body composition analysis and glucose and insulin tol-
erance tests were performed as described previously (Sansbury
et al., 2012).
BODY COMPOSITION
Body composition was measured by dual-energy X-ray absorp-
tiometry (Dexascan; PIXImus2; Lunar, Madison, WI) as
described previously (Sansbury et al., 2012; Cummins et al.,
2014).
METABOLOMIC ANALYSIS OF PLASMA
Whole blood was collected by cardiac ventricular puncture fol-
lowing a 16 h fast. EDTA was added to whole blood samples to
prevent coagulation, and plasma was separated from erythro-
cytes by centrifugation. Samples were stored frozen (−80◦C)
until metabolite extraction. After extraction in methanol, relative
metabolite abundance was measured by GC/MS or LC/MS/MS
by Metabolon, Inc. (Durham, NC) as described previously
(Cummins et al., 2014; Sansbury et al., 2014). Original scale data
(raw area counts) were then analyzed using Metaboanalyst 2.0
software (Xia and Wishart, 2011). Metabolites with missing val-
ues were imputed by replacing missing values with half of the
minimum positive value in the original data. Metabolites with
greater than 50% of the values missing were omitted from the
analysis. After a generalized logarithm transformation, the data
were autoscaled, i.e., mean-centered and divided by the stan-
dard deviation of each variable. After this transformation, the
distribution of the intensity values approximated a Gaussian dis-
tribution. The transformed values were used for univariate (e.g.,
volcano plots), multivariate (e.g., PCA), and cluster (heatmap
and dendogram) analyses. Z-scores were calculated from raw
area count spectral data from those metabolites that attained
significance in volcano plot analysis, using the Metaboanalyst
2.0 software (http://www.metaboanalyst.ca/) (Xia and Wishart,
2011).
PLASMA BILE ACID MEASUREMENTS
Total bile acids were measured using a liquid stable enzymatic col-
orimetric assay (Randox Laboratories, #BI3863) and analyzed by
a Cobas Mira Plus 5600 Autoanalyzer (Roche, Indianapolis, IN).
STATISTICAL ANALYSES
Data are presented as mean ± s.e.m. Multiple groups were com-
pared using One-Way ANOVA, followed by Bonferroni post-tests.
Unpaired Student’s t-test was used for direct comparisons. For
statistical analyses the Metaboanalyst and/or GraphPad 5.0 soft-
ware was used. A p ≤ 0.05 was considered significant.
RESULTS
EFFECTS OF HFD AND eNOS OVEREXPRESSION ON OBESITY
Wild-type and eNOS-TG mice were placed on a LFD or HFD for
6 weeks. As expected, feeding a HFD led to a two-fold increase
in the body weights of WT mice when compared with LFD con-
trols (p < 0.001; Figures 1A,B). While there was no difference
in weight gain between WT and eNOS-TG mice fed LFD, we
found that high fat-fed eNOS-TG mice gained less weight com-
pared with WT mice (Figures 1A,B). Indeed, Dexascan analyses
showed significantly less adiposity in high fat-fed eNOS-TG mice
thanWTmice fed a HFD, with a correspondingly higher percent-
age of lean mass (Figures 1C,D). This anti-obesogenic phenotype
of eNOS-TG mice was shown previously to be independent of
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FIGURE 1 | Overexpression of eNOS prevents diet-induced obesity.
(A) Body weights of wild type (WT) and eNOS-TG mice during 6
weeks of low (LFD) or high fat diet (HFD). (B) Summarized weight gain
after 6 weeks of LFD or HFD. (C) Body fat percentage and (D) lean
mass percentage following 6 weeks of diet measured by Dexascan
analysis. n = 7 per group; ∗∗∗p < 0.001 vs. indicated group; #p < 0.05,
##p < 0.01, and ###p < 0.001 vs. WT HFD.
changes in food consumption (Sansbury et al., 2012). Collectively,
these observations confirm our previous findings that overex-
pression of eNOS decreases adiposity and prevents weight gain
induced by HFD.
HFD AND eNOS OVEREXPRESSION SIGNIFICANTLY AFFECT THE
PLASMAMETABOLITE PROFILE
To examine how nutrient excess and eNOS overexpression affect
systemic metabolism, we measured the relative levels of 298 dif-
ferent metabolites in the plasma of 7 animals from each of the
experimental groups (i.e., WT mice fed a LFD; WT mice fed a
HFD; eNOS-TG mice fed a LFD, and eNOS-TG mice fed a HFD)
using an unbiased metabolomic approach. Principle component
analysis (PCA) was used to identify whether patterns in metabo-
lite abundance were sufficient to separate the groups. As shown
in the three-dimensional PCA score plot in Figure 2A, animals
within each group tended to cluster together and the metabolite
profile was sufficient to discriminate between each experimen-
tal group. Of the 298 metabolites measured, ANOVA revealed
that 116 metabolites were significantly different (Figure 2B and
Table 1), and hierarchical clustering heatmap and dendogram
analyses of the 50 most significantly changed metabolites revealed
both diet- and genotype-independent clustering (Figure 2C).
These analyses suggest that both the composition of the diet and
the eNOS transgene differentially regulate the metabolic profile.
EFFECTS OF HFD ON THE PLASMAMETABOLITE PROFILE
Because we found that both diet and eNOS regulate plasma
metabolites, we dichotomized the data and examined the effects
of diet in WT mice. Volcano plot analysis showed statistically
significant changes in 32 metabolites in mice fed a HFD for 6
FIGURE 2 | High fat feeding and eNOS overexpression significantly
affect the plasma metabolite profile. (A) Principal component
analysis of plasma metabolites of wild type (WT) or eNOS-TG mice
fed a low fat (LFD) or high fat diet (HFD). n = 7 per group. (B) Of
the 298 plasma metabolites measured, 116 were determined to be
significantly different by ANOVA, and these are displayed in the region
of the plot shaded red. Identities of metabolites found to be
significantly different are found in Table 1. (C) Hierarchical clustering
heatmap and dendogram analyses of the 50 most significantly
changed plasma metabolites. n = 7 per group.
www.frontiersin.org November 2014 | Volume 5 | Article 453 | 3
Sansbury et al. eNOS and systemic metabolism
Table 1 | List of plasma metabolites that changed significantly in WT
and eNOS-TG mice fed LFD or HFD.
Metabolite p-Value −10log(p) FDR
3-dehydrocarnitine 8.03e-11 10.095 2.10e-08
1,5-anhydroglucitol (1,5-AG) 3.14e-10 9.5027 4.10e-08
Mead acid (20:3n9) 1.92e-09 8.7159 1.67e-07
Pyridoxate 5.63e-09 8.2496 3.67e-07
Cinnamoylglycine 1.02e-08 7.9934 5.30e-07
Palmitoleate (16:1n7) 8.34e-07 6.0787 3.63e-05
Hippurate 1.04e-06 5.9835 3.63e-05
Alanylalanine 1.19e-06 5.9227 3.63e-05
Mannose 1.25e-06 5.9024 3.63e-05
Myristate (14:0) 3.54e-06 5.4511 9.24e-05
Stearoyl sphingomyelin 4.28e-06 5.3691 0.000101
Taurodeoxycholate 5.09e-06 5.2931 0.000111
3-indoxyl sulfate 9.15e-06 5.0386 0.000184
17-methylstearate 1.15e-05 4.9406 0.000214
Glycolate (hydroxyacetate) 1.54e-05 4.8131 0.000268
Dihomo-linoleate (20:2n6) 1.89e-05 4.7233 0.000308
Deoxycholate 2.22e-05 4.6541 0.00034
Palmitoyl sphingomyelin 3.66e-05 4.437 0.00053
Propionylcarnitine 4.09e-05 4.3886 0.000561
Cholate 4.43e-05 4.3533 0.000578
Linolenate [alpha or gamma;
(18:3n3 or 6)]
4.65e-05 4.3328 0.000578
2-palmitoleoylglycerophosphocholine 6.85e-05 4.1643 0.000813
Stearidonate (18:4n3) 7.85e-05 4.1049 0.000861
Alpha-tocopherol 7.91e-05 4.1016 0.000861
Linoleate (18:2n6) 8.98e-05 4.0466 0.000938
2-eicosatrienoylglycerophosphocholine 9.65e-05 4.0155 0.000969
2-aminoadipate 0.000148 3.8288 0.001434
Urea 0.000229 3.6399 0.002136
Dihomo-linolenate
(20:3n3 or n6)
0.000262 3.582 0.00235
7-alpha-hydroxy-3-oxo-4-
cholestenoate
(7-Hoca)
0.00027 3.5685 0.00235
Isovalerylcarnitine 0.000352 3.4531 0.002966
Glycerol 0.000377 3.4239 0.003073
1-palmitoleoylglycerophosphoethanolamine 0.000416 3.3809 0.00329
Taurocholate 0.000444 3.3526 0.003409
Margarate (17:0) 0.000479 3.3199 0.00357
Isobutyrylcarnitine 0.000715 3.146 0.005181
Taurochenodeoxycholate 0.000747 3.1269 0.005267
13-HODE + 9-HODE 0.000831 3.0805 0.005706
Cysteine 0.001067 2.972 0.007137
Gulono-1,4-lactone 0.001121 2.9505 0.007312
Xylose 0.001214 2.9158 0.007588
Phenol sulfate 0.001221 2.9133 0.007588
Docosapentaenoate (n3 DPA;
22:5n3)
0.0013 2.886 0.007854
Eicosenoate (20:1n9 or 11) 0.001324 2.8781 0.007854
Laurate (12:0) 0.001537 2.8132 0.008917
Butyrylcarnitine 0.001631 2.7875 0.009158
Docosahexaenoate (DHA;
22:6n3)
0.001649 2.7827 0.009158
Pantothenate 0.001918 2.7171 0.010308
Docosadienoate (22:2n6) 0.001935 2.7133 0.010308
Glucose 0.002037 2.6911 0.010632
Caprate (10:0) 0.002129 2.6719 0.010893
Carnitine 0.002204 2.6567 0.011064
Phenylalanine 0.002343 2.6303 0.011536
1-(3-aminopropyl)-2-pyrrolidone 0.002465 2.6082 0.011809
10-nonadecenoate (19:1n9) 0.002507 2.6008 0.011809
Eicosapentaenoate (EPA;
20:5n3)
0.002535 2.596 0.011809
P-cresol sulfate 0.002585 2.5876 0.011809
Cis-vaccenate (18:1n7) 0.002624 2.581 0.011809
Isoleucine 0.003002 2.5227 0.013278
Myristoleate (14:1n5) 0.003304 2.481 0.014339
(Continued)
Table 1 | Continued
Metabolite p-Value −10log(p) FDR
4-methyl-2-oxopentanoate 0.003351 2.4748 0.014339
1-arachidonoylglycerophosphoinositol 0.003807 2.4194 0.016025
1-palmitoleoylglycerophosphocholine 0.003871 2.4122 0.016036
Palmitate (16:0) 0.004039 2.3937 0.016473
Caprylate (8:0) 0.004348 2.3617 0.017459
Beta-muricholate 0.00446 2.3507 0.017637
Myo-inositol 0.004789 2.3197 0.018657
2-arachidonoylglycerophosphoethanolamine 0.004934 2.3068 0.018937
N-acetylphenylalanine 0.005072 2.2949 0.019184
Stearoylcarnitine 0.005207 2.2834 0.019334
1-eicosatrienoylglycerophosphocholine 0.005259 2.2791 0.019334
10-heptadecenoate (17:1n7) 0.00559 2.2526 0.019851
1-heptadecanoylglycerophosphocholine 0.005621 2.2502 0.019851
Hexadecanedioate 0.005628 2.2496 0.019851
Leucine 0.006128 2.2127 0.021326
Cysteine-glutathione disulfide 0.006518 2.1859 0.022383
Valine 0.007131 2.1469 0.024169
Campesterol 0.007414 2.13 0.024808
Glutamine 0.010255 1.9891 0.033879
Phosphate 0.010449 1.9809 0.034091
Pelargonate (9:0) 0.010797 1.9667 0.034791
Citrate 0.011349 1.9451 0.036104
2-oleoylglycerophosphocholine 0.011481 1.94 0.036104
3-methyl-2-oxobutyrate 0.012311 1.9097 0.038252
2-myristoylglycerophosphocholine 0.014728 1.8319 0.045223
Palmitoylcarnitine 0.016828 1.774 0.051072
1-stearoylglycerophosphocholine 0.017414 1.7591 0.052241
Gamma-glutamylglutamine 0.018021 1.7442 0.053449
2-linoleoylglycerophosphocholine 0.019827 1.7028 0.058143
N-acetyltryptophan 0.020569 1.6868 0.059651
Acetylphosphate 0.021677 1.664 0.062173
3-hydroxyisobutyrate 0.022059 1.6564 0.062581
2-palmitoylglycerophosphoethanolamine 0.022467 1.6484 0.062583
Methionine 0.022539 1.6471 0.062583
Proline 0.024342 1.6136 0.066876
Creatine 0.026059 1.584 0.070849
Uridine 0.027307 1.5637 0.073475
3-ureidopropionate 0.028624 1.5433 0.076232
Glycerophosphorylcholine (GPC) 0.029138 1.5355 0.076819
Gamma-glutamylleucine 0.033609 1.4735 0.087721
Glucuronate 0.033994 1.4686 0.087845
Corticosterone 0.035259 1.4527 0.090223
Urate 0.036642 1.436 0.092769
1-arachidonoylglycerophosphoethanolamine 0.037283 1.4285 0.092769
2-docosahexaenoylglycerophosphoethanol 0.037321 1.428 0.092769
amine
N1-methyladenosine 0.03905 1.4084 0.096151
Pentobarbital 0.040318 1.3945 0.097653
Histidine 0.040408 1.3935 0.097653
Gamma-glutamylisoleucine 0.041908 1.3777 0.10035
Threonate 0.043121 1.3653 0.10231
Hexanoylcarnitine 0.043571 1.3608 0.10245
EDTA 0.045224 1.3446 0.10539
Bradykinin, des-arg(9) 0.046511 1.3324 0.10743
Oleate (18:1n9) 0.047848 1.3201 0.10948
Cholesterol 0.04824 1.3166 0.10948
N-acetylleucine 0.048898 1.3107 0.11002
Wild-type (WT) or eNOS-TG mice on C57BL/6J backgrounds were fed a low
fat or high fat diet (LFD or HFD, respectively) for 6 weeks. Plasma was then
subjected to LC or GC mass spectrometric analysis. Plasma metabolites in mice
that were at least 50% changed in abundance and significantly different by One-
Way ANOVA are shown below. n = 28, with 7 mice per group.
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weeks (Figure 3A). Further assessment via Z-score plot analysis
demonstrated that many of the affected metabolites belonged to
the lipid superfamily, of which, the levels of numerous metabo-
lites in the lysolipid (e.g., 2-eicosatrienoylglycerophosphocholine,
1-palmitoleolyglycerophosphoethanolamine, 1-eicosatrienoylgly
cerophosphocholine, etc.) and bile acid (i.e., cholate, tauro-
cholate, beta-muricholate) subfamilies were lower in the HFD
group (Figure 3B). HFD also diminished several long-chain,
branched-chain, and dicarboxylate fatty acids. One lysolipid, 1-
heptadecanoylglycerophosphocholine, was higher in plasma of
high fat-fed mice, as were stearoylcarnitine, dihomolinoleate,
and palmitoyl- and stearoyl-sphingomyelin (Figure 3B). Notable
decreases in the marker of short-termmarker glycemic control, 1-
5-anhydroglucitol, were observed in mice fed a HFD (Figure 3C).
Also decreased were the amino acid superfamily members: 3-
indoxyl sulfate, N-acetylphenylalanine, and leucine. Higher abun-
dance of gamma-glutamylglutamine, gulono-1,4-lactone, cystine,
glycolate, and mannose were also observed in the plasma of high
fat-fed mice (Figure 3C).
EFFECTS OF eNOS OVEREXPRESSION ON THE PLASMAMETABOLITE
PROFILE
To evaluate effects of the eNOS transgene on metabolism, we
assessed changes in the plasmametabolome ofWT and eNOS-TG
mice fed a LFD (Figure 4A). As shown in the Z-score plots
in Figure 4B, we found an increase in the plasma levels of
13 metabolites in eNOS-TG mice, including 4 members of the
bile acid subfamily (7-α-hydroxy-3-oxo-cholestenoate, cholate,
deoxycholate, and taurodeoxycholate). Numerous branched
chain amino acid (BCAA) catabolites were higher in abundance
in eNOS overexpressing mice as well. These included 4-methyl-
2-oxopentanoate as well as several carnitine derivatives of BCAA
catabolic products, such as isobutyrylcarnitine, propionlycarni-
tine, and isovalerylcarnitine. The phenylalanine and tyrosine sub-
family members phenol sulfate and p-cresol sulfate were higher
in abundance, as was the B vitamin pantothenate (Figure 4C).
Lastly, the breakdown product of carnitine, 3-dehydrocarnitine,
was markedly increased in eNOS-TG mice compared with WT
mice.
Consistent with our previous studies showing a lower abun-
dance of circulating free fatty acids in eNOS-TG mice (Sansbury
et al., 2012), several long-chain fatty acids including stearido-
nate, eicosanoate, docosapentaenoate, linolenate, cis-vaccenate,
docosadienoate, eicosapentanoate, and dihomo-linolenate were
diminished in low fat-fed eNOS-TG mice compared with WT
controls (Figure 4B). Significantly diminished levels of numer-
ous lysolipids, xenobiotics (1-(3-aminopropyl)-2-pyrrolidone,
cyanurate), 2-aminoadipate, pyridoxate, alanylalanine, threonate,
FIGURE 3 | Effects of high fat feeding on the plasma metabolite
profile. Metabolomic analyses of plasma from wild type (WT) mice fed a
low fat (LFD) or high fat diet (HFD) for 6 weeks: (A) Volcano plot of
metabolites: Those metabolites that increased significantly are in the
region of the plot shaded red and those that decreased significantly are
in the region shaded green (p < 0.05, unpaired t-test); (B,C) Z-score plot
analysis of metabolite changes in plasma from low and high fat-fed mice,
separated by metabolite superfamily. Data are shown as standard
deviations from the mean of LFD. Only metabolites that increased or
decreased significantly and were changed by ≥50% are shown. Each
point represents one metabolite in one sample. n = 14 animals: 7 WT
LFD and 7 WT HFD.
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FIGURE 4 | Effects of eNOS overexpression on the plasma metabolite
profile. Metabolomic analyses of plasma from wild type (WT) and
eNOS-TG mice fed a low fat diet (LFD) for 6 weeks. (A) Volcano plot of
metabolites: Those metabolites that increased significantly are in the
region of the plot shaded red and those that decreased significantly are
in the region shaded green (p < 0.05, unpaired t-test); (B,C) Z-score plot
analysis of metabolite changes in plasma from low fat-fed WT and
eNOS-TG mice, separated by metabolite superfamily. Data are shown as
standard deviations from the mean of WT LFD. Only metabolites that
increased or decreased significantly and were changed by ≥50% are
shown. Each point represents one metabolite in one sample. n = 14
animals: 7 WT LFD and 7 WT HFD.
and α-tocopherol were also observed in plasma from eNOS-TG
mice (Figures 4B,C).
COMPARISON OF PLASMAMETABOLITES IN HIGH FAT-FED WT AND
eNOS-TG MICE
Differences in the plasma metabolite profile between WT and
eNOS-TG mice fed a HFD are perhaps most important for
understanding the systemic changes in metabolism that could
contribute to the anti-obesogenic effects of eNOS. Volcano
plot analysis of metabolites from high fat-fed mice showed 39
metabolites that were significantly different between the groups
(Figure 5A). Of all superfamilies, the amino acid superfamily
was most highly represented, with significant increases in
BCAAs (valine, leucine), BCAA catabolites (propionylcarnitine,
isobutyrylcarnitine, isovalerylcarnitine), metabolites in the urea
cycle (proline, ornithine, urea) and metabolites of the pheny-
lalanine and tyrosine subfamily (4-hydroxyphenylpyruvate,
N-acetylphenylalanine, p-cresol sulfate, 3-indoxyl sulfate)
(Figure 5B). Z-score analysis revealed that N-acetylleucine,
also a metabolic product in the BCAA pathway, and gamma-
glutamylleucine, a breakdown product of proteins in general,
were also increased in abundance in eNOS-TG mice. Amino acid
superfamily members that were decreased in abundance included
3-ureidopropionate, 2-aminoadipate, and butyrylglycine.
Plasma from high fat-fed, eNOS overexpressing mice showed
lower levels of free fatty acids and some lysolipids compared with
WT mice fed a HFD (Figure 5C), similar to changes observed
in low fat-fed counterparts (Figure 4). Outside of the lipid
and amino acid superfamilies, only 6 metabolites differed in
abundance between WT and eNOS-TG mice fed a HFD. Of
these, the levels of pyridoxate, 1-(3-aminopropyl)-2-pyrrolidone,
and glycolate (Figure 5D) were lower and the levels of xylose,
hippurate, and cinnamoylglycine were higher in eNOS-TG than
WT mice. The levels of corticosterone and 3-dehydrocarnitine
(Figure 5C) were also increased. However, the most striking
feature in high fat-fed eNOS-TG mice compared with WT mice
fed a HFD was an elevation in nearly all of the bile acids mea-
sured (Figure 5C). The levels of beta-muricholate, taurocholate,
cholate, taurochenodeoxycholate, taurodeoxycholate, and deoxy-
cholate were increased in eNOS-TGmice fed aHFD. To determine
if bile acids are directly responsible for the resistance of eNOS-TG
mice to diet-induced weight gain, we administered the farnesoid
X receptor (FXR) agonist GW4064, which was shown previously
to decrease bile acid abundance and promote obesity in C57BL/6J
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FIGURE 5 | Comparison of plasma metabolites in high fat-fed wild
type and eNOS-TG mice. Metabolomic analyses of plasma from WT
and eNOS-TG mice fed a high fat diet (HFD) for 6 weeks. (A) Volcano
plot of metabolites: Those metabolites that increased significantly are in
the region of the plot shaded red and those that decreased significantly
are in the region shaded green (p < 0.05, unpaired t-test); (B–D) Z-score
plot analysis of metabolite changes in plasma from high fat-fed WT and
eNOS-TG mice, separated by metabolite superfamily. Data are shown as
standard deviations from the mean of WT HFD. Only metabolites that
increased or decreased significantly and were changed by ≥50% are
shown. Each point represents one metabolite in one sample. n = 14
animals: 7 WT LFD and 7 WT HFD.
mice (Watanabe et al., 2011). Despite the fact that plasma bile
acid levels were decreased nearly five-fold by GW4064 in eNOS-
TG mice (Figure 6A), decreasing bile acid synthesis had no effect
HFD-induced weight gain during the 6 week feeding period
(Figure 6B) and did not affect fasting blood glucose levels or
glucose or insulin tolerance (Figure 6C). These data appear to
suggest that bile acids are not directly or exclusively responsible
for the resistance to weight gain imparted by high levels of eNOS.
Collectively, these results help define the impact of nutrient
excess and eNOS expression on systemic metabolism (Figure 7).
We found that feeding HFD led to significant increases in
body weight and adipose tissue mass (Figure 1), changes that
were accompanied by an increase in the circulating levels of
sphingomyelins and a decrease in the levels of lysolipids, bile
acids, some amino acid metabolites, and 3-dehydrocarnitine.
Overexpression of eNOS decreased lysolipids, 2-aminoadipate
and free fatty acids, but it increased the abundance of bile acids,
3-dehydrocarnitine, as well as BCAAs and their catabolic prod-
ucts. Importantly, the effects of eNOS overexpression on bile
acids appeared to be even more prominent when examined in the
setting of HFD, although changes in bile acids did not seem to
contribute to the lean phenotype of eNOS-TG mice.
DISCUSSION
The major goals of this study were to assess how nutrient
excess alters systemic metabolism and to understand how an
increase in NO modifies specific metabolic pathways in the con-
text of diet-induced obesity. Using an unbiased metabolomic
approach, we found numerous changes in lipid metabolites
caused by a HFD. Most notably, diet-induced obesity in
high fat-fed WT mice was accompanied by a decrease in
the circulating levels of bile acids and lysolipids. Conversely,
eNOS overexpression promoted higher levels of circulating
bile acids and also increased the abundance of BCAAs and
BCAA catabolic products. Because bile acids have been shown
to prevent adiposity, we hypothesized that eNOS overexpres-
sion stimulates bile acid synthesis, which in turn provides
intrinsic resistance to diet-induced obesity. However, eNOS-TG
mice remained lean on a HFD even when bile acid abun-
dance was decreased pharmacologically, suggesting that eNOS-
induced increases in bile acids are not solely responsible for
the anti-obesogenic phenotype related with high eNOS activ-
ity. Nevertheless, these observations do suggest that bile acid
production and amino acid metabolism are regulated by NO
and that processes that increase bile acids or other metabolic
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FIGURE 6 | Inhibition of bile acid synthesis does not promote
diet-induced obesity in eNOS-TG mice. The eNOS-TG mice were fed either
a HFD or a HFD containing GW4064 for 6 weeks followed by measurement
of: (A) Plasma bile acid levels; (B) body weight gain; and (C) (i) fasting blood
glucose, (ii) glucose tolerance test (GTT) area under the curve (AUC), and (iii)
insulin tolerance test (ITT) AUC. n = 4–6 per group. ∗p = 0.05 vs. TG HFD.
pathways may be important in mediating the anti-obesogenic
effects of NO.
The wealth of metabolic changes due to nutrient excess
and eNOS provides important information regarding systemic
metabolism. In particular, changes due to HFD alone could
be important for understanding the metabolic changes that
occur due to nutrient excess-mediated obesity. Several metabolic
changes indicate an insulin resistant phenotype caused by HFD.
For example, HFD promoted lower levels of 1,5-anhydroglucitol
(1,5-AG), a marker of glycemic control (Yamanouchi et al., 1996;
Stickle and Turk, 1997), which is indicative of systemic insulin
resistance and is in accordance with our previous studies show-
ing systemic glucose intolerance and insulin insensitivity in this
model (Cummins et al., 2014). As in our previous analysis of
adipose tissue (Cummins et al., 2014), we found that the plasma
levels of palmitoyl sphingomyelin and stearoyl sphingomyelin
were profoundly increased in obese mice. Interestingly, genetic
deletion of sphingomyelin synthesizing enzymes appears to pro-
tect against diet-induced obesity and insulin resistance (Li et al.,
2011; Mitsutake et al., 2011). The breakdown of sphingomyelin
could yield significant amounts of ceramide, which is a potent
inhibitor of insulin signaling (Chavez and Summers, 2012).
Hence, elevated levels of sphingomyelin could be a harbinger of
ceramide, which has been shown to be increased by 300% in
plasma of high fat-fed mice (Shah et al., 2008) and obese humans
(Haus et al., 2009).
Although lysolipids were clearly diminished in plasma from
high fat-fed WT mice, the significance of this finding to the phe-
notypic response to HFD is unclear. Lysophosphatidylcholines
(LysoPCs) weremost themost common lysolipid affected byHFD
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FIGURE 7 | Summary of the most significant changes in the plasma
metabolite profiles due to high fat feeding and eNOS
overexpression. The plasma metabolite changes in wild type (WT) mice
fed a high fat diet (HFD) compared with WT LFD are summarized in
the gray box. Plasma metabolite changes between WT LFD and
eNOS-TG LFD are displayed in the blue box. Metabolites that remained
significantly elevated in eNOS-TG HFD compared with WT HFD are
indicated by the asterisk.
in our study. LysoPCs are known to account for 5–20% of all
phospholipids in the serum (Kim et al., 2013) and have been
suggested to be closely associated with endothelial dysfunction,
oxidative stress, inflammation, atherogenesis, and obesity (Kim
et al., 2013). In our analysis, several species of lysoPC, includ-
ing lysoPC 16:1 and 18:1 were decreased while one, lysoPC 17:0,
was increased by HFD. These findings are in accordance with a
previous study that showed decreased levels of lysoPC 16:1 and
18:1, as well as lysoPC 14:0, 15:0, 16:0, 17:1, 18:2, 19:0, 20:1,
and 20:4, while lysoPC 17:0, 18:0, and 18:3 were increased in
diet-induced obese mice (Kim et al., 2011). Additional studies
have shown decreased serum levels of lysoPC 18:1 and increased
lysoPCs 14:0 and 18:0 in obese men (Kim et al., 2010) as well as
increased lysoPC 18:0 in high fat-fed pigs (Galili et al., 2007).
It is possible that the abundance of dietary lipids contained in
the HFD caused an increase in some forms of lysolipids, such as
lysoPC 17:0, which consists of one chain of margaric acid (derived
from lard) at the C-1 position. This could support the idea that
phospholipid remodeling took place in mice consuming HFD.
However, several of the same phospholipids were decreased in low
fat-fed eNOS-TG mice (Figure 4), which argues against the idea
that such lysolipid changes contribute to diet-induced obesity.
While no significant changes in fatty acids were observed in
high fat-fed WT mice, stearoylcarnitine was increased, which
could suggest an impairment of fat oxidation capacity. In eNOS
overexpressing mice, which exhibit increased energy expenditure
(Sansbury et al., 2012), decreases in numerous long-chain fatty
acids were observed. This is likely due, at least in part, to increased
utilization of fats, as genetic deletion of eNOS is known to impair
fat oxidation capacity (Le Gouill et al., 2007). It is also possible
that eNOS overexpression could inhibit fatty acid synthesis in the
liver (Sansbury and Hill, 2014). Nevertheless, the root cause for
such eNOS-induced changes in systemic fat metabolism is still
unclear.
Because of the established links of bile acid signaling on
energy expenditure (Watanabe et al., 2006), lipid and glucose
homeostasis (Watanabe et al., 2004; Zhang et al., 2006), and
obesity (Watanabe et al., 2006, 2011), we reasoned that changes in
the bile acid pathway could be important for the hypermetabolic
and anti-obesogenic effects of eNOS. Our analyses show that HFD
decreases bile acid abundance in WT mice and that overexpres-
sion of eNOS is sufficient to augment bile acid levels. The finding
that eNOS increases plasma levels of bile acids is supported by
studies showing that perfusion of livers with NO donors increases
bile acid outflow acutely (Trauner et al., 1997, 1998), while inhi-
bition of NOS reduces the biosynthesis of bile acids by inhibiting
the activity of hepatic Cyp7A1 (Khedara et al., 1998). Nitric
oxide has also been shown to inhibit bile acid uptake in hepa-
tocytes (Schonhoff et al., 2011). Metabolomic analyses showed
that both primary and secondary bile acids, e.g., cholate and
deoxycholate, as well as conjugated bile acids, e.g., taurodeoxy-
cholate, taurocholate, taurochenodeoxycholate, were increased in
eNOS-TG mice, suggesting that their hepatic synthesis, bacterial
dehydroxylation occurring in the gut, and conjugation in the liver
are increased under conditions of higher eNOS activity.
Notably, bile acids have been shown to lower triglycerides
by regulating FXR (Watanabe et al., 2004), and decreasing bile
acid pool size worsens obesity and diabetes in high fat-fed mice
(Watanabe et al., 2011). Moreover, mice overexpressing Cyp7A1,
a rate-limiting enzyme in bile acid synthesis (Lefebvre et al.,
2009), are resistant to diet-induced obesity, show elevated sys-
temic metabolism, and express higher levels of fat oxidation
genes (Li et al., 2010). In clinical trials, dyslipidemic patients
given bile acid-sequestering resins exhibited increased plasma
triglyceride and VLDL levels (Angelin et al., 1987; Crouse, 1987),
and patients with deficiencies in CYP7A1 are characterized by
increased plasma triglyceride concentrations (Pullinger et al.,
2002). Hence, we considered that eNOS-mediated resistance to
obesity and enhanced fat metabolism might be due to NO-
regulated elevations in the abundance of bile acids. However,
providing the synthetic FXR agonist GW4064—shown previ-
ously to be sufficient to decrease bile acid levels and energy
expenditure thereby accentuating diet-induced weight gain and
insulin resistance in mice (Watanabe et al., 2011)—was sufficient
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to decrease bile acids in eNOS-TG mice; however, the GW4064-
supplemented eNOS-TG mice maintained their lean phenotype
on HFD, and the drug did not affect glucose tolerance or insulin
sensitivity.
While these data suggest a bile acid-independent mechanism
for the anti-obesogenic effect of eNOS, there are several possibil-
ities and limitations to consider. For example, it is possible that
while bile acids are not directly responsible for promoting lean-
ness in eNOS-TG mice, effects secondary to their elevation could
play a role. For example, recent studies have unveiled impor-
tant roles for bile acids in regulating gut microbiota, which are
proving important for regulating energy metabolism, adipos-
ity, and insulin resistance (Li and Chiang, 2014). Hence, not
only are intestinal bacteria important for the synthesis of sec-
ondary bile acids, but bile acids themselves could influence the
microbiome and impact systemic metabolism. Although previ-
ous studies show that dietary administration of GW4064 for as
little as 3 weeks significantly increased diet-induced weight gain
(Watanabe et al., 2011), it is possible that the 6 week admin-
istration used in this study, although sufficient to decrease bile
acid abundance, was insufficient to reprogram metabolic changes
caused by bile acids, such as differential expression of intestinal
microbiota. Moreover, bile acids play an important role in xeno-
biotic metabolism (Chiang, 2013; Li and Chiang, 2014), which
can orchestrate energy metabolism (Gao and Xie, 2012) and
could alter obesogenic programs, even prenatally (Janesick et al.,
2014). Interestingly, eNOS overexpression was associated with
altered levels of several xenobiotic metabolites, such as hippurate,
1-(3-aminopropyl)-2-pyrrolidone, glycolate, cyanurate, and cin-
namoylglycine. Hence, while these studies appear to rule out a
direct causal effect of bile acids on eNOS-TG-induced resistance
to obesity, further studies are required to dissect their secondary
or long-term metabolic effects.
Other metabolic pathways affected by overexpression of eNOS
may also be important for regulating adiposity. In our analy-
sis, plasma levels of BCAAs and/or their short-chain catabolites
(e.g., 4-methyl-2-oxopentanoate) and acyl carnitine derivatives
(e.g., isobutyrylcarnitine, propionylcarnitine, isovalerylcarnitine)
were decreased in high fat-fed WT mice and increased in eNOS-
TG mice. This may be important because BCAA supplementa-
tion has been shown to have favorable effects on diet-induced
metabolic disease. For example, leucine supplementation pre-
vents obesity in rodents (Zhang et al., 2007; Vianna et al., 2012)
and is associated with lower adiposity in humans (Qin et al.,
2011), while isoleucine was shown to decrease tissue triglyc-
eride accumulation and adiposity and increase expression of
PPARα and uncoupling proteins in mice (Nishimura et al., 2010).
Additionally, increasing BCAA levels by deletion of BCATm, the
enzyme that catalyzes the first step in BCAA catabolism, com-
pletely prevents HFD-induced insulin resistance and adiposity
in mice, which was suggested to be due to a futile protein
turnover cycle (She et al., 2007). That this form of futile cycling
might occur in eNOS-overexpressing mice is suggested by eleva-
tions of not only BCAAs, but by increased abundance of protein
breakdown products such as gamma-glutamylleucine as well.
Furthermore, short-chain acylcarnitines, such as propionylcarni-
tine, were elevated in eNOS-TG mice, and these have been shown
to promote mitochondrial biogenesis and increase energy expen-
diture (Siliprandi et al., 1965; Sayed-Ahmed et al., 2000; She et al.,
2007; D’Antona et al., 2010). It should be noted, however, that
BCAAs have also been associated with increased insulin resis-
tance and metabolic risk factors in humans as well as rodents
(Newgard et al., 2009; Adams, 2011; Cheng et al., 2012). Thus, the
role of eNOS-induced changes in BCAAs and BCAA metabolites
on adiposity and insulin resistance requires further clarification.
Beyond BCAAs, eNOS-TGmice displayed several other metabolic
changes that could possibly play a role in regulating obesity.
For example, the eNOS-regulated increases in corticosterone or
3-dehydrocarnitine may be indicative of processes related with
steroidal- or carnitine-mediated processes that promote energy
expenditure and prevent excessive weight gain. Of interest, 2-
aminoadipate was decreased by eNOS and this metabolite has
been shown to be a biomarker for diabetes risk and to regulate
insulin and glucose homeostasis (Wang et al., 2013; Wu et al.,
2014). The importance of each of these pathways in mediating
the anti-obesogenic effects of eNOS remains to be tested.
In summary, this study identified significant changes due to
both nutrient excess and eNOS expression. High fat feeding in
WT mice diminished the abundance of lysophospholipids, bile
acids, BCAAs and their metabolites, and 3-dehydrocarnitine;
and HFD increased metabolic markers of insulin resistance and
oxidative stress. Overexpression of eNOS resulted in low lev-
els of numerous free fatty acids even in the face of nutrient
excess and led to remarkable elevations in the levels of bile acids
and BCAAs. These results further delineate systemic metabolic
changes induced by high fat diet and eNOS overexpression, which
could be built upon to develop targeted interventions to thwart
the obesity epidemic.
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